Juvabis is an IND-stage company that designs and develops a next generation of aminoglycoside antibiotics to overcome antimicrobial resistance and improve the safety of this drug class. Structural uniqueness of its proprietary leads warrants potent bactericidal activity against clinical pathogens that are resistant to all other aminoglycosides currently in clinical use, including 16S rRNA methyltransferase resistance often encountered in priority pathogens.
Another key differentiator of the Juvabis portfolio is an improved safety profile when compared to other aminoglycoside antibiotics, by virtue of a proprietary screening platform and rational lead optimization towards increased target selectivity. Juvabis strives to develop the best-in-class aminoglycoside antibiotics for highly developed healthcare systems, as well as providing innovative solutions for resource-limited settings in low- and middle-income countries.
Another key differentiator of the Juvabis portfolio is an improved safety profile when compared to other aminoglycoside antibiotics, by virtue of a proprietary screening platform and rational lead optimization towards increased target selectivity. Juvabis strives to develop the best-in-class aminoglycoside antibiotics for highly developed healthcare systems, as well as providing innovative solutions for resource-limited settings in low- and middle-income countries.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2016
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
EBL-1003 (apramycin) to treat Gram-negative systemic infections
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
